Helen Moon

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski et al. · Journal of Clinical Oncology · 2022 · 439 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2023 · 175 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde et al. · New England Journal of Medicine · 2024 · 145 citations · Full text

Medicine, Oncology, Surgery +14

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

Mohamad E. Allaf, Se-Eun Kim, Viraj A. Master et al. · The Lancet Oncology · 2024 · 82 citations · Full text

Medicine, Oncology, Surgery +10

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Toni K. Choueiri, Laurence Albigès, Philippe Barthélémy et al. · The Lancet · 2024 · 70 citations · Full text

Medicine, Oncology, Pharmacology +17